NCT07550985 Routine Probe Compression After Transrectal Prostate Biopsy(RPCAB) to Reduce Bleeding and Infectious Complications : A Randomized Controlled Trial
| NCT ID | NCT07550985 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Veterans Health Service Medical Center, Seoul, Korea |
| Condition | Prostate Biopsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 324 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2026-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 324 participants in total. It began in 2026-03-30 with a primary completion date of 2026-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hematuria (up to 50%) and rectal bleeding (up to 30%) are common complications following transrectal ultrasound-guided prostate biopsy. Although most cases are mild, some require additional intervention. Short-duration compression has been shown to achieve hemostasis in cases of post-biopsy bleeding, suggesting that routine probe compression may reduce bleeding complications. Post-biopsy bleeding may also be associated with an increased risk of subsequent infection. This randomized controlled trial aims to evaluate the effect of routine probe compression and compression duration after transrectal prostate biopsy on bleeding and infectious complications.
Eligibility Criteria
Inclusion Criteria: * Male patients aged ≥18 years Scheduled to undergo transrectal ultrasound-guided prostate biopsy Biopsy-naïve patients (first-time prostate biopsy) Able to provide written informed consent Exclusion Criteria: * Uncorrectable coagulopathy or bleeding disorder Active urinary tract infection at the time of biopsy Acute anorectal conditions (e.g., hemorrhoidal bleeding, anal fissure, proctitis) Inability to discontinue or appropriately manage anticoagulant or antiplatelet therapy History of severe drug allergy or hypersensitivity to medications used in the study Individuals unable to provide informed consent (e.g., cognitive impairment, medically incapacitated) or other vulnerable populations Participation in another interventional study related to prostate disease that may interfere with the outcomes of this study Severe comorbid conditions limiting study participation Inability to comply with follow-up procedures
Frequently Asked Questions
Who can join the NCT07550985 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Biopsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07550985 currently recruiting?
Yes, NCT07550985 is actively recruiting participants. Visit ClinicalTrials.gov or contact Veterans Health Service Medical Center, Seoul, Korea to inquire about joining.
Where is the NCT07550985 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07550985 clinical trial?
NCT07550985 is sponsored by Veterans Health Service Medical Center, Seoul, Korea. The trial plans to enroll 324 participants.